Vimarsana
Biggest News Aggregation in the World

Page 47 - Entrypoint Capital News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Entrypoint Capital. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Entrypoint Capital Today - Breaking & Trending Today

Insider Selling: ALX Oncology Holdings Inc. (NASDAQ:ALXO) Insider Sells 12,000 Shares of Stock - Vimarsana News

Insider Selling: ALX Oncology Holdings Inc. (NASDAQ:ALXO) Insider Sells 12,000 Shares of Stock

ALX Oncology Holdings Inc. (NASDAQ:ALXO – Get Free Report) insider Sophia Randolph sold 12,000 shares of ALX Oncology stock in a transaction that occurred on Monday, May 13th. The shares were sold at an average price of $15.94, for a total transaction of $191,280.00. Following the completion of the transaction, the insider now owns 330,349 […]

Source: wkrb13.com
PriceSmart, Inc. (NASDAQ:PSMT) Director Sherry S. Bahrambeygui Sells 522 Shares - Vimarsana News

PriceSmart, Inc. (NASDAQ:PSMT) Director Sherry S. Bahrambeygui Sells 522 Shares

PriceSmart, Inc. (NASDAQ:PSMT – Get Free Report) Director Sherry S. Bahrambeygui sold 522 shares of the stock in a transaction dated Monday, May 13th. The shares were sold at an average price of $85.71, for a total transaction of $44,740.62. Following the completion of the transaction, the director now directly owns 81,216 shares of the […]

Truist Financial Reiterates "Buy" Rating for Insmed (NASDAQ:INSM) - Vimarsana News

Truist Financial Reiterates "Buy" Rating for Insmed (NASDAQ:INSM)

Insmed (NASDAQ:INSM – Get Free Report)‘s stock had its “buy” rating restated by stock analysts at Truist Financial in a research note issued to investors on Thursday, Benzinga reports. They presently have a $48.00 price target on the biopharmaceutical company’s stock. Truist Financial’s price objective would suggest a potential upside of 92.38% from the stock’s […]

Insmed (NASDAQ:INSM) Stock Rating Reaffirmed by Truist Financial - Vimarsana News

Insmed (NASDAQ:INSM) Stock Rating Reaffirmed by Truist Financial

Insmed (NASDAQ:INSM – Get Free Report)‘s stock had its “buy” rating restated by analysts at Truist Financial in a report issued on Thursday, Benzinga reports. They presently have a $48.00 price target on the biopharmaceutical company’s stock. Truist Financial’s price objective indicates a potential upside of 92.38% from the company’s previous close. A number of […]

Source: wkrb13.com
Autolus Therapeutics (NASDAQ:AUTL) Trading 4.1% Higher - Vimarsana News

Autolus Therapeutics (NASDAQ:AUTL) Trading 4.1% Higher

Autolus Therapeutics plc (NASDAQ:AUTL – Get Free Report)’s share price was up 4.1% during mid-day trading on Thursday . The company traded as high as $4.15 and last traded at $4.09. Approximately 420,001 shares traded hands during mid-day trading, a decline of 75% from the average daily volume of 1,664,426 shares. The stock had previously […]